Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome
Status:
Terminated
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
This study will explore the safety and effectiveness of different doses of AGN 203818 in
treating the pain associated with fibromyalgia syndrome. The study is being conducted in 2
parts. Part A enrolled 211 pts dosed with either 3, 20, 60 mg BID AGN 203818 or placebo over
4 week treatment duration. Part B will enroll 440 pts and dose with either 20, 100, 160 mg
BID AGN 203818 or placebo over 12 week treatment duration.